CHP-Thesis by Alana, Allen Nichole Casanova
University of Tennessee, Knoxville
Trace: Tennessee Research and Creative
Exchange
University of Tennessee Honors Thesis Projects University of Tennessee Honors Program
Spring 5-2009
CHP-Thesis
Allen Nichole Casanova Alana
University of Tennessee - Knoxville
Follow this and additional works at: https://trace.tennessee.edu/utk_chanhonoproj
This is brought to you for free and open access by the University of Tennessee Honors Program at Trace: Tennessee Research and Creative Exchange. It
has been accepted for inclusion in University of Tennessee Honors Thesis Projects by an authorized administrator of Trace: Tennessee Research and
Creative Exchange. For more information, please contact trace@utk.edu.
Recommended Citation
Alana, Allen Nichole Casanova, "CHP-Thesis " (2009). University of Tennessee Honors Thesis Projects.
https://trace.tennessee.edu/utk_chanhonoproj/1249
Alana  1 
The Effects of Metallic Co-Factors on the Rate of Latency                            
and Stability of Plasminogen Activator Inhibitor-1 
 
Allen Nicole Casanova Alana, Cynthia Peterson,  
Sumit Goswami, Lawrence Thompson, Tihami Qureshi 
 The Department of Biochemistry, Cellular and Molecular Biology,  
The University of Tennessee, Knoxville 
 
Abstract. Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) 
that primarily inhibits the serine proteases tissue plasminogen activator (tPA) and 
urokinase plasminogen activator (uPA). Hence, it is an inhibitor of fibrinolysis, the 
physiological process that degrades blood clots. PAI-1 displays the classic serpin fold 
that includes a reactive center loop (RCL). It can be found in two main conformational 
states, active state and latent state. In its active form, the RCL is solvent accessible; in 
its latent form, the RCL is inserted as a strand into its central β sheet. PAI-1 also binds to 
its co-factor vitronectin, an abundant component of the extracellular matrix, which 
stabilizes PAI-1 in its active state. In this experiment, the stability of PAI-1 with 
vitronectin will be studied in the presence of various transition metals. In order to do this, 
a PAI-1 mutant is constructed with a cysteine replacing a serine at position 338 in the 
RCL (PAI-1S338C). This mutant is spin-labeled with methanethiosulfonate (MTSL) 
probe. The conformational change from active to latent state can then be detected via 
electron paramagnetic resonance (EPR) based on the hypothesis that metallic cofactors 
will destabilize the PAI-1 in its native form and will increase its rate of latency. Since 
vitronectin stabilizes PAI-1 in its active form and delays latency, binding of PAI-1 to 
vitronectin is expected to retard the increase in latency caused by the presence of 
metals.  
 
Background 
 PAI-1 belongs to the serine protease inhibitor (serpin) family. While the specificity 
of various serpins for its respective serine protease differs among family members, all 
serpins share the same basic form and function. The serpin fold characteristically 
consists of three β -sheets (sA-sC), nine α -helices (hA-hI), and a RCL containing the 
scissile bond at Arg346-Met347 (designated P1-P1'). The RCL imitates the natural 
substrate for target serine proteases. As an inhibitor, the scissile bond in the solvent-
exposed RCL of PAI-1 engages the active site of its target serine protease, is cleaved, 
and forms an acyl-enzyme complex. Concomitant with cleavage, the RCL of PAI-1 
inserts itself into the protein structure, translocating the serine protease to the opposite 
pole of the serpin, and effectively distorting its active site. A 1:1 serpin:serine protease 
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suicide - inhibitor complex is  formed. By this mechanism, PAI-1 inhibits the serine 
proteases tissue plasminogen activator (tPA) and urokinase plasminogen activator 
(uPA), which prevents the activation of plasminogen and consequently the dissolution of 
fibrin blood clots. Thus, the regulation of PAI-1 activity is important in the regulation of 
physiological processes 
 
 
Figure 1 Main Conformations of PAI-1. Following its inhibition of 
serine proteases, the RCL is inserted as a 4th strand into the 
central β-sheet A (s4A). The active and latent structures were 
constructed via Molecular Operating Environment (MOE) and are 
based on the 1B3K and 1C5G Protein Data Bank files, 
respectively. 
 
 
 
A mechanism to regulate the function of PAI-1 is inherent in its structure (Fig. 1). 
PAI-1 in its native/active form is metastable. In this form, the RCL of PAI-1 is solvent-
exposed. Due to the metastability of its active form, PAI-1 undergoes latency under 
physiological conditions, solvent-exposed. Due to the metastability of its active form, 
PAI-1 undergoes latency under physiological conditions in which the solvent-exposed 
RCL inserts as s4A without a change in covalent structure. Thus, loop insertion 
functions latency is affected by various organic cofactors. Vitronectin, a 75kDa 
glycoprotein, is a well-known binding partner of PAI-1. Binding of vitronectin stabilizes 
PAI-1 in its active state, increasing its half-life by one- to two-fold. Recent studies 
suggest that this stabilization may be due to vitronectin’s binding onto the RCL (Li, JBC, 
2008). The details are yet to be discovered.  
Alana  3 
 Another factor that affects the stability of PAI-1 is the absence or presence of 
transition metals. Evidence from experimentation in purifying PAI-1 protein indicates 
that the serpin retains the ability to bind metals, and mutagenesis studies have indicated 
a putative metal-binding site on PAI-1. Because of its metal-binding ability, it is 
hypothesized that metals may also affect the stability of the serpin. Current work in our 
lab provides evidence that certain transition metals, including copper, nickel, and cobalt, 
destabilize the active conformation of PAI-1 and increase its rate of latency (Fig. 2). 
Also, in a study of PAI-1 with metals in the presence of vitronectin, the effect of the 
latter’s stabilization of active PAI-1 is greatly enhanced (Thompson, unpublished 
results).  
 
Figure 2 Effects of Metal Co-Factors on 
PAI-1 half-life. The half-life of PAI-1 is 
measured indirectly through its ability to 
inhibit tPA. The half-life of control PAI-1 
is about 60 minutes without vitronectin 
and about 90 minutes with vitronectin. 
The transition metals iron, cobalt, 
nickel, and copper had the greatest 
effect on this value. Without vitronectin, 
there is a decrease in half-life and, 
thus, an increase in rate of latency. In 
the presence of vitronectin, these 
metals increases the half-life. This 
indicated a decrease in rate of latency. 
(Thompson, unpublished results)  
 
The goal of this project is to expand the study of metal effects on PAI-1 using electron 
paramagnetic resonance (EPR) spectroscopy. EPR spectroscopy is based on the 
electron spin of paramagnetic species, which is sensitive to the molecular environment. 
Thus, a spin probe containing a paramagnetic species will provide different signals due 
a difference in electron spin when it is unrestricted in mobility, such as in the RCL in the 
active form of PAI- 1, and when its spin is restricted, such as in the central β -sheet 
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where the RCL is inserted upon latency. Therefore, attaching a spin label to the RCL 
can be used to detect changes in the conformation of PAI-1, and thus its stability in the 
presence and absence of metals. In order to achieve the latter, a cysteine is engineered 
into the RCL at position 9 (P9) N-terminal from the scissile bond corresponding to Ser 
338. The rationale for creating this mutant resides in the ease of labeling the reactive 
thiol group of cysteine. Subsequently, the mutant PAI-1S338C is labeled with a 
methanethiosulfonate (MTSL) spin probe. It is hypothesized that metallic cofactors will 
destabilize PAI-1’s active form and increase its rate of latency. 
Experimental Procedures 
Site-Directed Mutagenesis by Polymerase Chain Reaction (PCR) 
Human wild-type PAI-1 was previously cloned into the pET24d(+) vector 
containing a kanamycin resistance marker for selection and the lac operator under the 
T7 promoter for ITPG induction. Wild-type PAI-1 does not contain any intrinsic cysteine 
residues, and thus, the serves as a convenient approach for labeling the serpin. In order 
to introduce this mutation, site-directed mutagenesis was performed using the 
QuikChange II XL Site-Directed Mutagenesis kit. Oligonucleotide primers were 
designed according to the manufacturer’s instructions to introduce a cysteine mutation 
to serine-338 in the wild-type PAI-1 sequence. This was followed by PCR in accordance 
to Table 1 below. 
 
Table 1: PCR Reaction Mixture 
Component Volume 
10x Reaction Buffer 5µL 
dsDNA template [pET24d(+)-PAI-1] 1µL from 20ng/µL stock 
Oligonucleotide Primer 1* 0.5µL from 298 ng/µL stock 
Oligonucleotide Primer 2* 0.5µL from 298 ng/µL stock 
Alana  5 
dNTP mix 1µL 
QuikSolution 3µL 
ddH2O 39µL 
 *Oligonucleotide Primer 1 and oligonucleotide primer 2 correspond to forward and reverse 
 sequences, respectively, that contain the desired mutation. 
 
 
 Thermocycling parameters, including stages of denaturation, annealing, and 
elongation, were set as indicated in Table 2: 
  
Table 2: PCR Reaction Cycling Parameters (18 Cycles)   
Temperature (˚C) Duration (seconds) 
95 60 
95 50 
60 50 
68 420 (1kb/min) 
68 420 
4 ∞ 
 
Following PCR, 1µL of the Dpn1 restriction enzyme was added to the reaction 
mixture to degrade the unmutated, methylated parent strands, while keeping the newly 
synthesized daughter strands with the desired mutation intact. The reactions were then 
incubated at 37˚C for 1 hour to complete degradation of the methlyated parent strands. 
Transformation & Verification of Mutated Sequence 
Escherichia coli XL10-Gold ultracompetent cells were used for the transformation 
with the mutated plasmids. This cell line has the following genotype: TetR Δ(mcrA) 183 
Δ(mcrCB-hsdSMR-mrr) 173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac The [F’ proAB 
laclqZΔM15 Tn10 (TetR) Amy].   
To perform the transformation, 45µL of the ultracompetent cells were transferred 
to a pre-chilled 14mL Falcon polypropylene round bottom tube and treated with 2µL β-
mercaptoethanol to increase its transformation efficiency. During this treatment, the 
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cells were incubated on ice for 10 minutes with swirling every 2 minutes. Following this 
short incubation period, 2µL of the Dpn-I treated PCR mixtures were added to the cells 
and incubated on ice for 30 minutes to allow the uptake of the uncut, mutated plasmids 
by the cells. A heat shock was then applied at 42˚C for 30 seconds, followed by 
incubation on ice for 2 minutes to signal cell wall repair and trap the mutated plasmids 
within the cells. 0.5mL of SOC media was then added and the solution was incubated at 
37˚C for 1 hour at 250rpm to promote growth. The transformation mixture was 
subsequently plated on Luria broth (LB) agar plates containing 50ug/µL of the antibiotic 
kanomycin and allowed to grow overnight at 37˚C.  
 Upon successful transformation indicated by growth on the above plate, a mutant 
screen and selection was performed.  Colonies from this plate were picked at random 
and placed in 10mL of Terrific Broth (an enriched LB medium), to which 50ug/µL 
kanomycin was added, and incubated at 37˚C overnight at 250rpm. Following the 
overnight incubation, the cells were harvested by centrifugation at 14,000 x g for 10 
minutes at room temperature. The Promega Mini Prep Kit was then used to isolate the 
plasmids from the cells. The protocol included in this kit contains the following steps: 
addition of 500µL of the cell resuspension solution to the cell pellet, which was then 
resuspended by vortex; addition of 500µL of the cell lysis solution and mixing by 
inversion; addition of 20µL of alkaline protease, mixing by inversion, and incubating five 
minutes at room temperature; addition of 700µL of the neutralization solution and mixing 
by inversion; centrifugation at 14,000 x g for 30 minutes at room temperature; transfer of 
supernatant to a spin column and application of a vacuum; washing with 2mL of column 
wash solution; drying for 10 minutes via vacuum; and elution with 100µL of nuclease-
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free water by centrifuge for 1 minute at 10,000 x g at room temperature. Approximately 
131 – 230 ng/µL of DNA was obtained per preparation. Sequencing was perfomed via 
the Sangster dideoxynucleotide chain termination and separated by capillary 
electrophoresis and. Plasmids containing the cysteine mutation at position 338 (S338C) 
were thus identified and confirmed. 
Transformation of pET24(d+)-PAI-1 S338C into E. Coli Rosetta 2 DE3 pLysS 
Competent cells 
 E. Coli Rosetta 2 DE3 pLysS [genotype F- ompT hsdSB(RB- mB-) gal dcm 
λ(DE3 (lacI lacUV5-T7 gene 1 ind1 sam7 nin5) pLysSRARE (CamR)] were transformed 
by adding 1µL of the verified pet24d(+)-PAI-1 S338C plasmid DNA to 50µL of the cells, 
which were obtained from -80˚C and thawed on ice. Subsequently, the transformation 
mixture was incubated on ice 30 minutes. A heat pulse was applied at 42˚C for 1 
minute, which was followed by incubation on ice for 4 minutes. 0.5mL of SOC media 
was then added and the mixtures were allowed to incubate at 37˚C for 1 hour at 
250rpm. Upon completion incubation, the cells were plated on LB plated containing 
50ug/µL kanomycin and 34ug/µL chloramphenical, inverted, and incubated at 37˚C 
overnight. 
Growth & Expression E. Coli Rosetta 2 DE3 pLysS- pET24(d+)-PAI-1 S338C 
Upon successful transformation indicated by growth on the above plate, growth 
and expression trials for the construct were performed. Colonies were selected from this 
plate and placed in 200mL TB supplied with 50ug/µL kanomycin and 34ug/µL 
chloramphenical and allowed to incubate at 28˚C at 250rpm overnight to an OD600 of 
0.7. The cells were then subcultured to 1L of fresh TB, containing 50ug/µL kanomycin 
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and 34ug/µL chloramphenical, to an OD600 of 0.01. The culture was incubated at 37˚C 
at 250rpm and the OD600 was periodically checked and recorded in Table 3 below: 
 
Table 3: Growth of E. coli Rosetta 2 DE3 pLysS pET24(d+) PAI-1 S338C 
Time (hours) OD600 
0 0.01 
2 0.45 
2.2 0.91* 
3.2 1.91 
             
   *At OD600 of 0.91, culture cooled to 15˚C at 250rpm 
 
At mid-log phase, corresponding to an OD600 of 1.91, cells were induced with 
1mM IPTG and incubated at 15˚C with shaking at 250rpm for 18 hours. The OD600 of the 
cultures were read periodically during induction, and recorded in Table 4: 
 
Table 4: Induction of E. coli Rosetta 2 DE3 pLysS pET24(d+) PAI-1 S338C 
Time (hours) OD600 
0 1.91 
1 2.1 
2 2.5 
7 4.8 
18 7 
 
To verify induction, samples taken at the various time points recorded in Table 3 
and Table 4 were boiled with 4X SDS reducing dye, loaded on a 10% polyacrylamide 
gel, and SDS-PAGE was performed by running the samples at 150V for 1 hour. 
Subsequently, the gel was overlain on a nitrocellulose membrane and transferred at 
20V for 5 minutes. Subsequently, the gel was stained by coomassie dye and destained 
Alana  9 
in destain buffer (30 % methanol, 7.5 % acetic acid). A Western blot was performed on 
the nitrocellulose membrane in four steps: blocking, addition of primary antibody, 
addition of secondary antibody, and developing. To prevent nonspecific and background 
interactions by blocking, 10% milk was added to the membrane and incubated for 1 
hour at room temperature with gentle shaking. This step was followed by three washes 
with phosphate buffered saline in 0.1%Tween 80 (PBS-tween). The primary antibody 
(rabbit anti-human PAI-1) that specifically binds to PAI-1 was then added at 
concentration of 1:5000 in 2% milk in PBS, allowed to incubate at room temperature for 
30 minutes with gentle shaking, and wash three times with PBS-tween The secondary 
antibody (peroxidase-labeled anti-rabbit) for detection was then added at a 
concentration of 1:3000 in 2% milk in PBS, incubated at room temperature for an 
additional 30 minutes with gentle shaking, and washed as previously. Following 
incubation with the antibodies, the western blot was developed with 30mL of PBS, 6mL 
of 4-chloro-1-naphthol in 3mg/mL methanol, and 20µL of hydrogen peroxide. The 
results of the SDS-PAGE and western blot are recorded in the following section.  
Following induction after 18 hours, the E. coli Rosetta 2 DE3 pLysS pET24(d+) 
PAI-1 S338C cells were harvested by centrifuge at 10,000rpm for 30 minutes at 4˚C.  
The obtained 65g of pellet from the cell harvest was then stored in -80˚C pending 
purification. 
Purification of PAI-1 S338C protein from E. coli Rosetta 2 DE3 pLysS cells 
 PAI-1 S338C protein was purified from E. coli Rosetta 2 DE3 pLysS cells as 
described in the following paragraphs. All procedures were performed at 4˚C to prevent 
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latency transition and in the presence of the reducing agent dithiothreitol (DTT) to 
prevent disulfide formation of the PAI-1 cysteine mutant.  
 For purification of PAI-1 S338C protein, the cell pellet harvested after IPTG 
induction as previously described was resuspended in 650mL of a lysis buffer 
containing 50mM NaH2PO4, 1mM of the divalent chelator EDTA, and 1mM DTT at a pH 
of 6.5. To this solution, 650mg of protease inhibitor cocktail (for use with bacterial cell-
extracts, Sigma Aldrich) to prevent protease degradation of the PAI-1 protein and 20mg 
of lysozyme to facilitate cell wall lysis was added. The cells were then covered and 
resuspended on stir plate at room temperature for 1 hour. Following resuspension, the 
cells were placed on ice and lysed via vibrations by sonication at an amplitude of 7 for 
20 pulses, with 30 seconds on and 1 minute off. The lysate then centrifuged at 
10,000rpm for 30 minutes and the supernatant was collected. Purification of the PAI-1 
mutant was then achieved through three steps, which includes ion exchange, 
immobilized metal affinity chromatography (IMAC), and gel filtration.  
Ion exchange, specifically cation exchange, was performed on a SP-Sepharose 
column. Since the isoelectric point (pI) of the PAI-1 S338C mutant is 7.1, the pH of the 
column was set to 6.5 so that it will be positively-charged and bind to the negatively-
charged column. This step separates the desired protein from most E. coli proteins, 
which have a pI lower than this pH, and thus will not bind to the column. The column 
[column volume(CV)=100ml] was equilibrated with a SP-Sepharose buffer containing 
80mM (NH4)2SO4, 50mM NaH2PO4, 1mM EDTA, and 1mM DTT at pH 6.5. The 
supernatant was then loaded onto the column at 10mL/min and flowed through. The 
column was then washed with approximately 5 CV of the SP-Sepharose Buffer until the 
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detector returned to baseline. A 80-500mM (NH4)2SO4 gradient was then applied to lute 
and then 10mL fractions were collected. The A280 of the fractions were read and an 
elution profile was constructed. The fractions 64-80 corresponding to a peak on the 
elution profile was analyzed by SDS-PAGE and western blot as previously described. 
Upon verification, the latter peak containing PAI-1 was pooled. In preparation for the 
next purification step employing IMAC, the EDTA, which could chelate the metal on the 
column, was dialyzed out in an imidazole buffer containing 20mM imidazole (C3H4N2), 
50mM NaH2PO4, 500mM NaCl, and 1mM DTT at pH 7 (or imidazole buffer) overnight at 
4˚C. 
 IMAC was performed on a chelating Sepharose column to which nickel (II) was 
bound. Although the PAI-1 S338C mutant constructed does not contain a His-tag, this 
step was used because of the ability of PAI-1 to bind metals. To the chelating 
sepharose column (CV=20mL), 0.2M NiSO4 was added at a flow rate of 5mL/min to 
bind Ni2+ to the column. The excess nickel was washed off the column with 50mM 
CH3COO·∙Na and 500mM NaCl at a pH of 4. The column was then equilibrated with the 
imidazole buffer. Once equilibrated and the pH of the column reached 7, the dialyzed 
protein was loaded onto the column and flow through at a rate of 5mL/min. 
Subsequently, the column was washed with the imidazole buffer until detector reached 
a baseline. A 20-120mM imidazole gradient was then applied to elute and 10mL 
fractions were collected in tubes containing 500mM KH2PO4, 300mm NaCl, and 30mM 
EDTA, pH 6.25. The A280 of the fractions were read and an elution profile was 
constructed. The fractions were analyzed by SDS-PAGE and western blot as previously 
described. The peak of fractions 1 – 11 containing the desired PAI-1 protein and a few 
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other proteins of sufficiently different molecular weight were pooled. Because of the 
latter size differences, final separation and purification was achieved by gel filtration. 
Prior to this step, the pool was concentrated to 3 mL with a 30kDa membrane. 
Gel filtration was performed on a S-100 column (CV=500mL). The column was 
first equilibrated with 50mM NaH2PO4, 300mM NaCl, 1mM EDTA, and 1mM DTT, pH 
6.25. The concentrated protein was then loaded onto column at 0.5mL/min and 3mL 
fractions were collected. The A280 of the fractions were read, an elution profile was 
constructed, and SDS PAGE followed by western blot was performed as previously 
described. The fractions 100-111 containing pure PAI-1 were pooled, concentrated with 
a 30kDa membrane, aliquoted, and stored at -80˚C. 
PAI-1 S338C Gel-Based Activity Assay with tPA  
To check the activity the purified protein, an activity assay with tPA was 
performed.  tPA and purified PAI-1 S338C mutant protein were obtained from -80˚C and 
allowed to thaw on ice. Stock solutions for tPA and the PAI-1 mutant were prepared in 
accordance to Table 5 below: 
  
Table 5: Activity Assay Reaction Mixtures 
tPA:PAI-1 ratio PAI-1 (µM) Volume of 12 µM PAI-1 Stock (µL) 
Volume of 1X 
PBS Buffer (µL) 
1 : 0.5 2 3.33 16.67 
1 : 0.75 3 5.00 15.00 
1 : 1 4 6.67 13.33 
1 : 1.25 5 8.33 11.67 
1 : 1.5 6 10.00 10.00 
1 : 2 8 13.33 6.67 
1 : 3 12 20.00 0.00 
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These separate mixtures were incubated at room temperature for 1 hour. 
Following incubation, the mixtures were analyzed on a 10% polyacrylamide gel by SDS-
PAGE gel under both reducing and non-reducing conditions. The results of the activity 
assay are provided in the next section.  
 Spin-Labeling of PAI-1 S338C with MTSL probe 
Prior to labeling, the DTT from the PAI-1 S338C protein stock must be removed. 
A PD-10 Column was thus used, and equilibrated by gravity with a PD-10 buffer 
containing 40mL of 300mM NaCl, 50mM NaH2PO4, and 1mM EDTA, pH 6.25. 2.5mL of 
the PAI-1 mutant protein with a concentration of 1.31 was loaded onto the column and 
the flow-through was discarded. Another 3mL of PD-10 buffer was added onto the 
column and the flow-through was collected. The protein was then concentrated down to 
a volume of 2mL using a Biomax-10 column with a 10kDa cut-off. Methanethiosulfonate 
(or MTSL) was used as the spin label. Labeling of PAI-1 S338C with MTSL was 
performed as follows: 37mM of MTSL was added such that its final volume would be ten 
times that of the protein. The solution was then placed on ice for at least 3 hours. 
Another PD-10 Column was equilibrated with 40mL of the PD-10 buffer via gravity. The 
now-labeled PAI-1 mutant was loaded onto the column and the flow-through was 
discarded. Another 3mL of the PD-10 buffer was then added and the flow-through was 
collected. The Abs280 was then read to determine concentration of the protein, which 
was further concentrated with separate Biomax-10 columns with a 10kDa cut-off. 
Verification of MTSL-PAI-1 S338C by Matrix-Assisted Laser Desorption/Ionization 
(MALDI) Mass Spectrometry 
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 A high-performance liquid chromatography (or HPLC) was first performed to 
isolate the labeled protein. 50µL of the protein was loaded and the specific sequence is 
described in Table 6. 
 
Table 6: HPLC Run Sequence 
Time (min) % Acetonitrile (0.085% TFA) 
0 5 
3 5 
18 95 
20 95 
23 5 
30 5 
 
For MALDI, a matrix solution (20mg of sinapic acid in 1mL of 50:50 acetone and 
acetonitrile solution) was mixed with the labeled PAI-1 S338C protein at a 1:1 ratio. The 
MALDI was calibrated with trypsinogen, Protein A, and BSA. The labeled protein was 
subsequently analyzed by MALDI and the results recorded.  
Electron Paramagnetic Resonance (EPR) Spectroscopy  
Upon verification of labeling of PAI-1 S338C with MTSL by MALDI, dialyzation 
into a EPR buffer containing 50mM tricine, 150mM NaCl, and 1mM EDTA, pH 6 was 
performed overnight at 4˚C. The Abs280 and subsequent concentration of the solution 
was obtained and recorded. 
 Solutions of NiCl2, CoCl2, and CuCl2 were created at 14mM each in the EPR 
buffer. These metal solutions, MTSL-labeled PAI-1, and EPR buffer solutions kept on 
ice and added immediately before the EPR run in order to obtain a complete and 
accurate change in the PAI-1 activity. The EPR reaction mixtures were created in 
accordance to Table 7 below such that the final volume for each would be 80µL.  
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Table 7: EPR Reaction Mixtures 
Trial Description PAI-1 14mM NiCl 
14mM 
CoCl 
14mM 
CuCl 
EPR 
Buffer 
PAI-1 only 33 - - - 47 
Co only - - 40 - 40 
PAI-1 + Co 33 - 22.9 - 24.1 
Ni only - 40 - - 40 
PAI-1 + Ni 33 22.9 - - 24.1 
Cu only - - - 40 40 
PAI-1 + Cu 33 - - 22.9 24.1 
 
The parameters for the runs were held as such: attenuator 30db, receiver gain 
5.02 x 105, modulator frequency 100kHz, amplitude 4G, time constant 327.68ms, 
resolution 512, and scans 4. The results from the EPR experiments were collected and 
recorded below.  
Results and Data 
Transformation & Verification of Mutated Sequence 
 
Figure 3 Amino acid sequence of 
the desired PAI-1 mutant with a 
projected molecular weight of 
42758.8587 daltons, the theoretical 
pI is 6.97. This was created from 
PeptideMass with no enzyme 
cutting and all cysteines in reduced 
form.  
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Purification  
Figure 4 Purification analysis of 
PAI-1S338C via 10%SDS-PAGE 
and Western Blot. PAI-1S338 
(43kDa) was purified and 
compared to the standard (Std) 
and the supernatant (SN). This 
purification process of the PAI-1 
protein has three main steps.  
     1. Cation Exchange (SP-
Sepharose Pool column) where 
PAI-1 is separated based on its 
charge. 
     2. Immobilized Metal Affinity 
Chromatography (Ni2+-
Sepharose Pool column) where 
separation is based on the metal 
binding site on PAI-1 for divalent 
cations. 
     3. Gel Filtraion (S100 Pool 
Column) where separation is 
based on PAI-1’s size. 
 
Gel-Based Activity Assay with tPA  
 
 
 
 
 
 
Figure 6 Activity Assay of PAI-1 utilizing Tissue 
Plasminogen Activator (tPA)  tPA (shown above as 
“C”) is a dimer that has a significant role in 
fibrinolysis. As a serine protease, it is inhibited by 
PAI-1 (shown above as “B”) and subsequently forms 
a 1:1 tPA:PAI-1 complex (shown above as “A”). The 
amount of this inhibitor:substrate complex formed as 
the tPA:PAI-1 ratio increases reflects the activity of 
this protein mutant. 
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Removal of DDT & Spin-Labeling 
 
 
 
Figure 7 Abs280 of mutant PAI-1 solution 
after MTSL labeling The absorbance at 
280nm of a 1:10 dilution of the desired 
mutant PAI-1 was taken and recorded as 
0.125. The actual absorbance was then 
calculated as 1.25 and the concentration 
of PAI-1 is 1.31mg/mL or 28.5 µM. 
 
 
 
 
 
Matrix-Assisted Laser Desorption/Ionization (MALDI) Verification 
 
 
 
Figure 8 HPLC Results A 50µL aliquot 
of the mutant PAI-1 was injected into 
the HPLC and the output at 
approximately 15 minutes (as indicated 
in the figure) was collected. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 Matrix-assisted laser desorption/ ionization 
(MALDI) verification. Calibrated with trypsinogen, 
Protein A, and BSA, this ionization technique 
confirmed that the MTSL spin-label successfully form 
a peptide bond with the point mutation of PAI-
1S228C. The percent error of the experimental and 
theoretical combined masses of the protein and 
MTSL is 0.078. This error comes mainly from the 
calibration of the standard. 
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Dialyzation into EPR Buffer  
 
 
Figure 10 Abs280 of mutant PAI-1 solution 
after Dialyzation into the EPR buffer The 
absorbance at 280nm of the desired mutant 
PAI-1 was taken and recorded as 1.076 (as 
indicated by the arrow). The actual 
absorbance was then calculated as 0.974 
after the baseline was subtracted. The 
concentration of PAI-1 is 1.047mg/mL or 
22.7 µM. 
 
 
 
 
 
Electron Paramagnetic Resonance (EPR) Spectroscopy 
Table 8: EPR Raw Data 
Signal Intensity (x103) Sample 
Description 
Time 
(minutes) Maximum Minimum Δ Amplitude (x10
3) 
0 21.72 -21.54 43.26 
30 20.03 -19.26 39.29 
60 19.6 -16.75 36.35 
10µM PAI-1 
90 17.66 -15.05 32.71 
0 15.71 -13.17 28.88 
30 12.08 -10.32 22.4 
60 10.02 -10.04 20.06 
10µM PAI-1 + 
4mM Co 
90 8.79 -9.63 18.42 
0 20.12 -20.28 40.4 
30 19.28 -18.12 37.4 
60 15.28 -15.04 30.32 
10µM PAI-1 + 
4mM Ni 
90 10.98 -10.17 21.15 
0 15.44 -15.69 31.13 
30 11.80 -12.46 24.26 
60 11.10 -10.19 21.29 
10µM PAI-1 + 
4mM Cu 
90 9.86 -8.01 17.87 
 
Sample Description Δ0-Δ30 Δ30-Δ60 Δ60-Δ90 Δtotal % Difference 
10µM PAI-1 3.97 2.94 3.64 10.55 24.38742487 
10µM PAI-1 + 4mM Co 6.48 2.34 1.64 10.46 36.21883657 
10µM PAI-1 + 4mM Ni 3 7.08 9.17 19.25 47.64851485 
10µM PAI-1 + 4mM Cu 6.87 2.97 3.42 13.26 42.59556698 
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Figure 11 Amplitude vs 
Time (minutes) The change 
in the various samples’ 
change in signal intensity is 
graphed in relation to the 
change in time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 EPR 
Signal Intensity in 
Comparison to 
PAI-1 The effects 
of the metal co-
factors on PAI-1 is 
graphed at the 
respective times. 
The bar represents 
the percent 
difference between 
the metal + PAI-1 
and PAI-1 alone.  
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Figure 13 EPR Spectroscopy Results. The paramagnetic signal of 10µM spin-labeled PAI-1S338 was 
checked at 0, 30, 60, and 90 minutes. 4mM of CoCl, NiCl, and CuCl was then added to 10µM spin-
labeled PAI-1S338 and checked at the same time interval to determine any change in the rate of latency. 
There was a significant drop in signal intensity (determined as the amplitude of the second major peak) in 
the metal:PAI-1 solution. The percent differences of the PAI-1:metal complex signal to the PAI-1 signal 
was then determined.  
 
Conclusion and Future Experiments 
The basis and success of this experiment is reliant upon PAI-1’s distinct 
conformations as active and latent. The construct of the mutant PAI-1 was specifically 
designed to take advantage of the protein’s self-insertion of the RCL. The purification 
steps verified that the protein in the solution was, in fact, the PAI-1 desired. The activity 
assay showed that not all of the PAI-1 was active; however, the EPR results proved that 
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proved that there was enough active PAI-1S338C in the solution to give a 
distinguishable signal. The MALDI results showed that the protein was indeed labeled 
with the MTSL. By having the spin label attached to this portion of the protein, the EPR 
would be able to clearly tell when the protein is active (a strong signal) and when the 
protein is inactive (a comparably weaker of absence of signal). The signal strength of 
MTSL is additive and therefore will be much more pronounced with a solution of active 
PAI-1 than a solution with a majority of inactive PAI-1. After a successful growth and 
harvest of the PAI-1 mutant, the various purifications and spin-labeling procedures 
allowed for a stable and ideal protein specimen for this experiment.  
Future experiments focus on including vitronectin with the EPR spectroscopy to 
see how the vitronectin-PAI-1 stability factor interacts with how metal co-factor stabilizes 
PAI-1 in its latent form. Also, extending the time interval over ninety minutes would give 
a better picture of the changing rate of latency. Expanding the range of metals to 
include both transition and alkaline (and biologically present) would also be beneficial to 
the experiment by giving a broader perspective on metal interaction and how the 
differing metal properties affect PAI-1’s rate of latency.  
